AKT1 and liver cancer: Treatment with APS (25 μg/mL) combined with 10 μmol/L of the Akt inhibitor LY294002 for 72 h reduced the survival rate of HepG2 cells to 13.4%, suggesting that APS may regulate autophagy in liver cancer cells by modulating autophagy-related genes and the key signalling pathways.